Takeshita T, Inoue H, Miyazono N, Hori A, Harada O, Satake M, Kanetsuki I, Nishida H, Sagara K, Shinmaki H
Department of Radiology, Faculty of Medicine, Kagoshima University, Japan.
Gan To Kagaku Ryoho. 1992 Sep;19(11):1867-72.
Seventeen patients with hepatocellular carcinoma were treated by intraarterial injection of CTL suspension. The doses of CTL suspension, CDDP and THP(mean +/- SD)/injection were 4.1 +/- 1.6 ml, 81.9 +/- 31.6 mg and 13.5 +/- 5.2 mg, respectively. The therapy was given once in 10 patients, twice in 6 and 4 times in one. Over 50 per cent reduction in tumor size was obtained in 5 patients (30%). Fifty or more % decrease in serum alpha-feto-protein (AFP) levels was observed in 3 of 7 patients (43%) with the initial serum AFP level of more than 200 ng/ml, Fever, abdominal pain, nausea and vomiting were noted in most cases. However, they disappeared within 2 weeks after therapy was completed. No severe complications were encountered except one case of a liver abscess which healed by administration of antibiotics. No severe changes in laboratory data were observed. This study suggests that a new method of intraarterial injection must be developed to enhance the therapeutic effect even more, in addition to an increased injection dose of CDDP/THP-LPD and higher concentration of CDDP and THP in LPD.
17例肝细胞癌患者接受了经动脉注射CTL悬浮液治疗。CTL悬浮液、顺铂（CDDP）和吡柔比星（THP）的注射剂量（均值±标准差）分别为4.1±1.6 ml、81.9±31.6 mg和13.5±5.2 mg。10例患者接受1次治疗，6例接受2次治疗，1例接受4次治疗。5例患者（30%）肿瘤大小缩小超过50%。7例初始血清甲胎蛋白（AFP）水平超过200 ng/ml的患者中，3例（43%）血清AFP水平下降50%及以上。多数病例出现发热、腹痛、恶心和呕吐，但在治疗结束后2周内消失。除1例肝脓肿经抗生素治疗愈合外，未出现严重并发症。实验室数据未观察到严重变化。本研究表明，除了增加CDDP/THP-LPD的注射剂量以及LPD中CDDP和THP的浓度外，还必须开发一种新的经动脉注射方法以进一步提高治疗效果。
